Keywords: immutep, begins, ph, immufact, cancer, study, french

Immutep begins Ph I ImmuFact cancer study

Article | 14 August 2006

Print This

French biopharmaceutical group Immutep SA says that its lead product, ImmuFact (IMP321), has entered a Phase I trial as a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in